Inflammatory Bowel Diseases (IBD), comprising Crohn's disease (CD) and ulcerative colitis (UC) are chronic, immune-mediated conditions characterized by relapsing inflammation of the gastrointestinal tract. Their complex pathogenesis involves a dynamic interplay of genetic predisposition, environmental triggers, microbial dysbiosis, and dysregulated immune responses. Despite therapeutic advances, IBD remains lifelong diseases with a significant impact on patients' quality of life and healthcare systems [1,2].

The introduction of biologics, including anti-tumor necrosis factor (TNF), anti-integrin, anti-interleukin (IL)-12/23 agents, and more recently, small molecules like Janus Kinase (JAK) inhibitors and Sphingosine-1-Phosphate (S1P) receptor modulators, has significantly improved the management of moderate-to-severe IBD. These therapies offer targeted mechanisms and the potential for steroid-free remission and mucosal healing. However, their efficacy is limited: each approved agent is effective in about 30–40 % of patients. This limited efficacy across drug classes has led to the recognition of a “therapeutic ceiling”, a plateau in clinical benefit beyond which additional improvements with current mechanisms of action appear marginal. Alongside this, important unmet needs persist: high relapse rates, treatment-related toxicity, lack of predictive biomarkers for response and persistent impact on functional outcomes and quality of life [3].

In light of these challenges, there is growing interest in emerging therapies that go beyond biologics and small molecules as well as complementary strategies. New prospects include immune cell reprogramming, epithelial barrier restoration, microbiome-targeted interventions and cell- or gene-based therapies. Such approaches aim to overcome existing limitations by addressing previously untargeted pathways and mechanisms [3,4].

This review explores these next-generation therapeutic options, evaluating their potential to expand the treatment landscape of IBD and to break through the current therapeutic ceiling, ultimately aiming for durable remission, disease modification, and improved long-term outcomes for patients.